A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

Study K36-MCRPC-001 is the first in human clinical trial testing KTX-2001 alone and with darolutamide in men with metastatic castration-resistant prostate cancer. The study aims to assess whether the drug is safe, increasing doses alone and in combination with darolutamide, whether it is effective in treating metastatic castration-resistant prostate cancer, and measuring how the drug(s) behaves in the body.

Trial Details

NCT ID
NCT07103018
Phase
PHASE1
Sponsor
K36 Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • KTX-2001
  • KTX-2001 + Darolutamide (NUBEQA®)
Locations (sample)
  • San Francisco, California, United States|37.77493,-122.41942
  • Miami, Florida, United States|25.77427,-80.19366
  • Port Saint Lucie, Florida, United States|27.29393,-80.35033
  • Rochester, Minnesota, United States|44.02163,-92.4699
  • New Hyde Park, New York, United States|40.7351,-73.68791

Key Eligibility Criteria

  • Age ≥18 years.
  • Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.
  • Male participants with mCRPC as defined by PCWG3 criteria.
  • Metastatic disease documented using bone scan for bone metastases (PCWG3 criteria) or by computed tomography (CT) or magnetic resonance imaging (MR…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →